Icure Pharmaceutical (XKRX:175250) Debt-to-Equity : 1.41 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical Debt-to-Equity?

Icure Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩70,359 Mil. Icure Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩5,262 Mil. Icure Pharmaceutical's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩53,564 Mil. Icure Pharmaceutical's debt to equity for the quarter that ended in Mar. 2024 was 1.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Icure Pharmaceutical's Debt-to-Equity or its related term are showing as below:

XKRX:175250' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.82 Max: 2.57
Current: 1.41

During the past 10 years, the highest Debt-to-Equity Ratio of Icure Pharmaceutical was 2.57. The lowest was 0.24. And the median was 0.82.

XKRX:175250's Debt-to-Equity is ranked worse than
91.49% of 846 companies
in the Drug Manufacturers industry
Industry Median: 0.295 vs XKRX:175250: 1.41

Icure Pharmaceutical Debt-to-Equity Historical Data

The historical data trend for Icure Pharmaceutical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical Debt-to-Equity Chart

Icure Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.87

0.52

0.76

0.95

1.31

Icure Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.84	0.93	0.98	1.31	1.41

Competitive Comparison of Icure Pharmaceutical's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Icure Pharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Icure Pharmaceutical's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Icure Pharmaceutical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Icure Pharmaceutical's Debt-to-Equity falls into.

Icure Pharmaceutical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Icure Pharmaceutical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(71512.263	+	4896.425)	/	58237.723
	=	1.31

Icure Pharmaceutical's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(70359.128	+	5261.65)	/	53563.864
	=	1.41

Icure Pharmaceutical (XKRX:175250) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Icure Pharmaceutical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Icure Pharmaceutical (XKRX:175250) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR

Website

https://www.icure.co.kr

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical (XKRX:175250) Headlines

No Headlines